Aspen CEO discusses H1 results, J&J vaccine production & COVID-19 legacy

With the Covid-19 Pandemic becoming a new reality, pharmaceuticals have had to play an important role. Aspen released their half year results, and they have recorded an interesting set of numbers. The company’s total headline earnings per share are down 18 per cent while revenue, rose 17 per cent. Aspen CEO, Stephen Saad joins CNBC Africa for more.

Mon, 15 Mar 2021 11:02:24 GMT
Sign Up for Our Newsletter Daily Update
Get the best of CNBC Africa sent straight to your inbox with breaking business news, insights and updates from experts across the continent.
Get this delivered to your inbox, and more info about about our products and services. By signing up for newsletters, you are agreeing to our Terms of Use and Privacy Policy.